China’s Health Security Administration said on Sunday that talks to include Pfizer’s Paxlovid in the latest drug list for basic state health insurance did not succeed.
The talks fell through was due to Pfizer’s high quotation for Paxlovid. Pfizer did not immeditately respond to a request to comment.
(This story has not been edited by Newsd staff and is auto-generated from a syndicated feed.)
